Company Overview
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Why Investors Should Care
Generates a return on equity of 16.5%, reflecting efficient use of shareholder capital.
Operating margin of 27.0% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $25.12B (+11.2% YoY); net profit $3.25B.
- Trailing 12 Months Year-on-year growth — revenue +9.4%, earnings +44.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.3%, profit CAGR 6.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.28% |
| 1 Year: | 9.40% |
Compounded Profit Growth
| 5 Years: | 6.66% |
| 1 Year: | 44.10% |
Stock Price Performance
| 1 Year: | -19.19% |
| 6 Months: | -16.40% |
| 3 Months: | -0.56% |
| 1 Month: | -10.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)34.07 · Neutral
P/E of 31.41 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SYK Stryker Corporation SPXR3KPHARMA | 303.13 | 31.41 | $116.27B | 1.04% | 12.21% | 16.51% | 8.28% | 6.66% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 2.96B | 3.01B | 3.01B | 3.47B | 3.24B | 3.32B | 3.24B | 3.80B | 3.52B | 3.65B | 3.59B | 4.13B | 3.59B | 2.76B | 3.74B | 4.26B | 3.95B | 4.29B | 4.16B | 4.70B | 4.28B | 4.49B | 4.48B | 5.20B | 4.78B | 5.00B | 4.91B | 5.82B | 5.24B | 5.42B | 5.49B | 6.44B | 5.87B | 6.02B | 6.06B | 7.17B | 6.02B | 6.59B |
| Gross Profit | 1.87B | 2.09B | 1.96B | 1.99B | 1.98B | 2.24B | 2.14B | 2.19B | 2.15B | 2.46B | 2.28B | 2.38B | 2.33B | 2.70B | 2.33B | 1.55B | 2.46B | 2.72B | 2.51B | 2.77B | 2.64B | 3.04B | 2.73B | 2.83B | 2.78B | 3.24B | 3.02B | 3.18B | 3.16B | 3.70B | 3.33B | 3.42B | 3.52B | 4.17B | 3.74B | 3.84B | 3.85B | 4.63B | 3.81B | 4.50B |
| Operating Income | 486.00M | - | 556.00M | 502.00M | 525.00M | - | 591.00M | 672.00M | 576.00M | - | 528.00M | 613.00M | 628.00M | - | 635.00M | -20.00M | 859.00M | - | 459.00M | 732.00M | 574.00M | - | 447.00M | 772.00M | 808.00M | - | 735.00M | 965.00M | 931.00M | - | 972.00M | 1.05B | 1.08B | - | 837.00M | 1.11B | 1.14B | - | 936.00M | 1.66B |
| Net Income | 355.00M | 510.00M | 444.00M | 391.00M | 434.00M | -249.00M | 443.00M | 452.00M | 590.00M | 2.07B | 412.00M | 480.00M | 466.00M | 725.00M | 493.00M | -83.00M | 621.00M | 568.00M | 302.00M | 592.00M | 438.00M | 662.00M | 323.00M | 656.00M | 816.00M | 563.00M | 592.00M | 738.00M | 692.00M | 1.14B | 788.00M | 825.00M | 834.00M | 546.00M | 654.00M | 884.00M | 859.00M | 849.00M | 745.00M | 1.28B |
| Diluted EPS | 0.94 | 1.34 | 1.17 | 1.03 | 1.14 | -0.66 | 1.16 | 1.19 | 1.55 | 5.44 | 1.09 | 1.26 | 1.23 | 1.90 | 1.30 | -0.22 | 1.63 | 1.49 | 0.79 | 1.55 | 1.14 | 1.73 | 0.84 | 1.72 | 2.14 | 1.47 | 1.54 | 1.93 | 1.80 | 2.98 | 2.05 | 2.14 | 2.16 | 1.41 | 1.69 | 2.29 | 2.22 | 2.20 | 1.93 | 3.30 |
| R&D Expense | 184.00M | - | 192.00M | 192.00M | 198.00M | - | 204.00M | 216.00M | 221.00M | - | 225.00M | 246.00M | 246.00M | - | 254.00M | 233.00M | 242.00M | - | 288.00M | 310.00M | 306.00M | - | 413.00M | 351.00M | 364.00M | - | 339.00M | 346.00M | 353.00M | - | 368.00M | 363.00M | 377.00M | - | 405.00M | 407.00M | 410.00M | - | 413.00M | 434.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.00B | 6.72B | 6.72B | 7.32B | 8.31B | 8.66B | 9.02B | 9.68B | 9.95B | 11.32B | 12.44B | 13.60B | 14.88B | 14.35B | 17.11B | 18.45B | 20.50B | 22.59B | 25.12B |
| Gross Profit | 4.14B | 4.59B | 4.54B | 5.03B | 5.50B | 5.88B | 6.02B | 6.36B | 6.60B | 7.50B | 8.18B | 8.94B | 9.70B | 9.06B | 10.97B | 11.58B | 13.06B | 14.44B | 16.07B |
| Operating Income | 1.31B | 1.52B | 1.59B | 1.75B | 1.69B | 1.74B | 1.26B | 1.25B | 1.86B | 2.17B | 2.30B | 2.54B | 2.71B | 2.22B | 2.58B | 2.84B | 3.89B | 3.69B | 4.89B |
| Net Income | 1.02B | 1.15B | 1.11B | 1.27B | 1.34B | 1.30B | 1.01B | 515.00M | 1.44B | 1.65B | 1.02B | 3.55B | 2.08B | 1.60B | 1.99B | 2.36B | 3.17B | 2.99B | 3.25B |
| Diluted EPS | 2.44 | 2.78 | 2.77 | 3.19 | 3.45 | 3.39 | 2.63 | 1.34 | 3.78 | 4.35 | 2.68 | 9.34 | 5.48 | 4.20 | 5.21 | 6.17 | 8.25 | 7.76 | 8.40 |
| R&D Expense | 375.30M | 367.80M | 336.00M | 394.00M | 462.00M | 471.00M | 536.00M | 614.00M | 625.00M | 715.00M | 787.00M | 862.00M | 971.00M | 984.00M | 1.24B | 1.45B | 1.39B | 1.47B | 1.62B |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 7.60B | 9.07B | 10.66B | 12.15B | 13.21B | 15.40B | 17.26B | 16.22B | 20.43B | 22.20B | 27.23B | 30.17B | 34.33B | 34.63B | 36.88B | 39.91B | 42.97B | 47.84B |
| Total Equity | 4.19B | 5.38B | 5.41B | 6.60B | 7.17B | 7.68B | 8.60B | 9.05B | 8.60B | 8.51B | 9.55B | 9.97B | 11.73B | 12.81B | 13.08B | 14.88B | 16.62B | 18.59B | 20.63B | 22.42B |
| Cash & Equivalents | 416.60M | 290.50M | 701.00M | 659.00M | 1.76B | 905.00M | 1.40B | 1.34B | 1.79B | 3.38B | 3.32B | 2.54B | 3.62B | 4.34B | 2.94B | 2.94B | 1.84B | 2.97B | 3.65B | 4.01B |
| Long Term Debt | - | - | - | 18.00M | 996.00M | 1.75B | 1.75B | 2.74B | 3.25B | 3.23B | 6.69B | 6.59B | 8.49B | 10.23B | 13.23B | 12.47B | 11.86B | 10.90B | 12.19B | 14.86B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | 7.71B | 10.88B | 12.22B | 15.50B | 17.36B | 21.25B | 19.75B | 20.27B | 21.32B | 22.34B | 25.42B |
| Current Liabilities | - | - | 1.46B | 1.44B | 1.60B | 1.84B | 1.88B | 2.66B | 4.46B | 3.50B | 3.15B | 3.48B | 4.81B | 4.40B | 5.04B | 4.55B | 6.30B | 7.92B | 7.62B | 7.79B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.03B | 1.18B | 1.46B | 1.55B | 1.43B | 1.66B | 1.89B | 1.78B | 981.00M | 1.92B | 1.56B | 2.61B | 2.19B | 3.28B | 3.26B | 2.62B | 3.71B | 4.24B | 5.04B |
| Investing Cash Flow | -1.18B | 310.10M | -1.33B | -795.00M | -2.13B | -736.00M | -2.22B | -1.88B | 1.96B | -4.19B | -1.61B | -2.86B | -1.46B | -4.70B | -859.00M | -2.92B | -962.00M | -3.00B | -4.87B |
| Financing Cash Flow | 13.60M | -1.05B | -193.00M | 410.00M | -161.00M | -449.00M | 300.00M | 629.00M | -1.22B | 2.26B | -794.00M | 1.33B | 3.00M | -11.00M | -2.37B | -749.00M | -1.59B | -525.00M | 113.00M |
| Capital Expenditure | -187.70M | -155.20M | -131.00M | -182.00M | -226.00M | -210.00M | -195.00M | -233.00M | -270.00M | -490.00M | -598.00M | -572.00M | -649.00M | -487.00M | -525.00M | -588.00M | -575.00M | -755.00M | -761.00M |
| Free Cash Flow | 840.60M | 1.02B | 1.33B | 1.36B | 1.21B | 1.45B | 1.69B | 1.55B | 711.00M | 1.43B | 961.00M | 2.04B | 1.54B | 2.79B | 2.74B | 2.04B | 3.14B | 3.49B | 4.28B |
| Share Buybacks | 0 | 1.00B | 0 | 426.00M | 622.00M | 108.00M | 317.00M | 100.00M | 700.00M | 13.00M | 230.00M | 300.00M | 307.00M | 0 | 0 | - | - | - | - |
| Dividends Paid | 89.70M | 135.60M | 198.00M | 238.00M | 279.00M | 324.00M | 401.00M | 462.00M | 521.00M | 568.00M | 636.00M | 703.00M | 778.00M | 863.00M | 950.00M | 1.05B | 1.14B | 1.22B | 1.28B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 68.9% | 68.3% | 67.5% | 68.8% | 66.2% | 67.9% | 66.7% | 65.7% | 66.4% | 66.3% | 65.7% | 65.7% | 65.1% | 63.1% | 64.1% | 62.8% | 63.7% | 63.9% | 64.0% |
| Operating Margin % | 21.8% | 22.6% | 23.7% | 23.9% | 20.3% | 20.1% | 13.9% | 12.9% | 18.7% | 19.2% | 18.5% | 18.7% | 18.2% | 15.5% | 15.1% | 15.4% | 19.0% | 16.3% | 19.5% |
| Net Margin % | 17.0% | 17.1% | 16.5% | 17.4% | 16.2% | 15.0% | 11.2% | 5.3% | 14.5% | 14.5% | 8.2% | 26.1% | 14.0% | 11.1% | 11.7% | 12.8% | 15.4% | 13.2% | 12.9% |
| ROE % | 18.9% | 21.2% | 16.8% | 17.7% | 17.5% | 15.1% | 11.1% | 6.0% | 16.9% | 17.2% | 10.2% | 30.3% | 16.3% | 12.2% | 13.4% | 14.2% | 17.0% | 14.5% | 14.5% |
| ROCE % | - | 24.7% | 20.9% | 19.3% | 16.4% | 15.4% | 9.9% | 9.7% | 14.6% | 12.6% | 12.3% | 11.3% | 10.5% | 7.6% | 8.6% | 9.3% | 12.2% | 10.4% | 12.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.15% | 27.41M | $9.07B |
| 2 | Vanguard Capital Management LLC | 5.88% | 22.54M | $7.45B |
| 3 | JPMORGAN CHASE & CO | 4.50% | 17.26M | $5.71B |
| 4 | State Street Corporation | 4.05% | 15.53M | $5.14B |
| 5 | Greenleaf Trust | 3.97% | 15.23M | $5.04B |
| 6 | Price (T.Rowe) Associates Inc | 3.11% | 11.92M | $3.94B |
| 7 | Vanguard Portfolio Management LLC | 2.13% | 8.17M | $2.70B |
| 8 | Wellington Management Group, LLP | 2.13% | 8.17M | $2.70B |
| 9 | Geode Capital Management, LLC | 2.04% | 7.82M | $2.59B |
| 10 | Morgan Stanley | 1.55% | 5.96M | $1.97B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SYK
Stryker Corporation (SYK) Stock Analysis: Exploring a 26% Upside Potential Amidst Strong Buy Ratings - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxPV2Rlb0Exa3FBcjNETVRNanVCcXNneG5Wbjlwd3I1NGJzU3dNaXFWcVpuRmdaWDk3Y2gxcktyZVdyYzZ4ckxaVnYwMWNSM3A3cWRNQlpnRlBZTzBuTHJzQ3NZakxqQm82VnNKbnpOTHZQRFhFaERYVEFZYzJxb3lTY0FUcGZkN014Qkx5ST…
Hsbc Holdings PLC Raises Stock Position in Stryker Corporation $SYK - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOVDNxSXUxeVFfcnNXRVhmczJxWDVacmhJOERYNVdTeXV2cXk4MjZRWUVHUU9uYVNNZWF5OEhiMGNaQzJOcGxaOVVaN1UwbDZKT1hJbUpBM2pidVRXMTh2NktxV1kxRV9jMDdOTFAzbG50cGt6RkEyOUhQdkJwNU9PQzZxXzNWci1yNXN5bi…
More than 150 million patients are impacted annually by Stryker. Executives speak Sept. 8. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQY3pnYU9FNDVySXh5dGlQNWhHY3ljVTc2TThMN2ZJcERxRkpzSFBqTWZQUVpwLTlETjJfa1RQUVBaRTNOMzFLUVlYTE4wc1JCTFhxTXZaZ0NMd0pLS2RZUnVDX0lNR0tFSzUxQ0xjU28yWjRzdFpISDhaVXdXenhhenJVSElraHpsVUtneF…
Stryker (SYK) Stock Looks Like A Bargain Near Fair Value - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQckpXcW15d2l3LTZkZ1JWcTFjQ203ZGpTTTFscXF5SjlkS3F0NXVYZTdhd3c2MmtIdnNCTTRWX3hZMVczZi15ZGtIVW9fem95T25OeUR4LThlMW14MzB1MU9hc3VOay1XZFUxSFRfbXdLNktsQ0NIUVdHY2RvUk81MVlVSjZiWmJEcVg3em…
Medical Devices & Supplies - Diversified Stocks Q2 Teardown: Stryker (NYSE:SYK) Vs The Rest - TradingView
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxNeEpvRzBVTnl4bDlmSzkyajY3ZE9IVW1ZcFYzOEphQjR5elNfUVNSdXVfWU8yT2dud2t5bGlLTUJTNlEtaW4wV3gzTkdmNjdUSmgtTDBUWVR6WW11MHVDdG5obm42UHB3YmVmS25GUVoxMXoyQzhoUWtMS0N2U3JOWkh0czRsYmVjWEhGeX…
HighTower Advisors LLC Has $153.01 Million Stake in Stryker Corporation $SYK - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNU3JyQWMzMkExWG9fenppdl9qUXNSQWFUbFBRMmNvcTJxU1JnUVVzQmNqVDducGlqTHVEd1VMbG9ULW9zWjk2UzUzR2dTZG9aU1U0UTFKSHFGNmxJbkRwLVdhR0M2c0puTnlEaUdsSXFKU1pCRkhZcEhNVzV0VExiZFZKdDlyQlVYLVpEQV…
SYK — Frequently Asked Questions
What is the current share price of Stryker Corporation (SYK)?
As of 2026-09-07 16:24 PDT, Stryker Corporation (SYK) trades at $303.13 on NYSE. Its 52-week range is $281.83 to $390.37.
What is the market capitalisation of SYK?
Stryker Corporation (SYK) has a market capitalisation of $116.27B on NYSE.
What is the P/E ratio of SYK?
SYK trades at a trailing price-to-earnings (P/E) ratio of 31.41. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.66.
Does SYK pay a dividend?
Stryker Corporation (SYK) currently offers a dividend yield of 1.04%.
What is the return on equity (ROE) of SYK?
SYK has a return on equity (ROE) of 16.51%. Its return on capital employed (ROCE) is 12.21%.
Is SYK a good stock to buy?
This page provides a data-driven analysis of Stryker Corporation (SYK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.